Medical and Pharmacy Drug Management

Latest Resource

Medical and Pharmacy Drug Management Resources

As the pharmacy benefit management industry undergoes the most significant transformation in decades, employers are at the forefront of driving change. This vendor engagement template equips them with information to […]

The Pulse of the Purchaser study gauges concerns and approaches of employers to address the workforce environment; whole person health, equity, women’s health, mental health and obesity management; fiduciary perspectives; pharmaceutical […]

As healthcare costs increase, employers and other plan sponsors continue to explore strategies to better manage pharmaceutical costs. Given that prescription drug spending accounts for 18% of all healthcare spending, […]

For decades the PBM industry has been plagued by misalignment, opacity, and consolidation. Rather than improving drug value and creating an efficient marketplace, the industry has fueled a flawed model […]

On Tuesday, June 4, the House Energy and Commerce Oversight and Investigations subcommittee hosted a hearing to discuss the 340B Drug Pricing Program.  National Alliance President and CEO Shawn Gremminger submitted a […]

The private sector is bringing new expertise and momentum to an effort once thought impossible—the end of the HIV epidemic in the U.S. It’s going to take leaders across business […]

Coalitions In Action

Membership in the National Alliance is a catalyst for state and regional coalitions and their employer/purchaser members to advance key initiatives. Together, they leverage their collective influence to drive health, equity and value.

Pharmacy and Medical Drugs

Defining and Driving Value

The National Alliance works with policymakers, employers/purchasers, and other stakeholders across the pharmacy and medical drug supply chain to influence competition, transparency, and value. Current issues of focus include pharmacy benefit manager (PBM) performance, contracting and formulary management, biosimilars, reducing waste, pharmacogenomics, and value-based benefit design.

The initiatives focus on practices affecting both pharmacy and medical benefits, with a strong emphasis on the rising costs of healthcare, hospital pricing, and prescription drugs. For example, the National Alliance has recently been engaging with policymakers to provide insights on the 340B program, its impact on escalating healthcare expenses for working families and employers, and potential areas for reform.

Explore these additional resources for a deeper look at the 340B program’s impact on healthcare costs and reform initiatives.